- Sees Q4 charge in the range of USD 20-35mln pretax
- Sees about USD 0.02 charge.
- Elsewhere, the company has stopped one of three phase 3 Rheumatoid Arthritis registration, cites did not meet efficacy views.
Print 13:01, 13 Dec 2012 - US Equities - Source: Newswires
RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: